Ironsides Asset Advisors’s VanEck Biotech ETF BBH Stock Holding History

Ironsides Asset Advisors’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,940	Closed	-$273K	–	91
2022 Q3	$273K	Hold	1,940	–	–	0.12%	62
2022 Q2	$283K	Hold	1,940	–	–	0.11%	64
2022 Q1	$315K	Hold	1,940	–	–	0.1%	71
2021 Q4	$367K	Hold	1,940	–	–	0.1%	60
2021 Q3	$392K	Buy	1,940 +420	+28%	+$88.2K	0.12%	58
2021 Q2	$307K	Hold	1,520	–	–	0.09%	72
2021 Q1	$267K	Hold	1,520	–	–	0.08%	78
2020 Q4	$258K	Sell	1,520 -95	-6%	-$15.7K	0.08%	69
2020 Q3	$262K	Hold	1,615	–	–	0.08%	69
2020 Q2	$263K	Hold	1,615	–	–	0.09%	70
2020 Q1	$207K	Sell	1,615 -1,910	-54%	-$257K	0.13%	62
2019 Q4	$491K	Buy	+3,525	New	+$463K	0.15%	60

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TIA

Traphagen Investment Advisors Oradell, New Jersey $1.4B AUM 19.32% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

PGFC

Peapack-Gladstone Financial Corp Bedminster, New Jersey $7.82B AUM 21.06% 1-Year Est. Return

CIG

Consolidated Investment Group Englewood, Colorado $922M AUM 28.87% 1-Year Est. Return

Ironsides Asset Advisors's BBH Position: Q4 2022 in Review

Ironsides Asset Advisors sold out of VanEck Biotech ETF (BBH) in Q4 2022, closing a stake of 1,940 shares — an estimated $273K sold.

Ironsides Asset Advisors first reported a position in BBH in Q4 2019 and held it in 12 quarters. The position peaked at $491K in Q4 2019. 120 funds tracked by Wall St. Rank hold BBH as of Q4 2022.

Ironsides Asset Advisors reported no remaining VanEck Biotech ETF position as of Q4 2022 after selling out during the quarter.
Ironsides Asset Advisors sold 1,940 VanEck Biotech ETF shares in Q4 2022, an estimated $273K.
Ironsides Asset Advisors first reported a position in VanEck Biotech ETF in Q4 2019 and held it in 12 quarters.
Ironsides Asset Advisors's VanEck Biotech ETF position peaked at $491K in Q4 2019.
120 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2022.

Based on Ironsides Asset Advisors's 13F filing for Q4 2022, filed 3 Feb 2023.